Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 166 AL 180

Amyloid-beta immunotherapy: the hope for Alzheimer disease?

Barrera-Ocampo A, Lopera F.

Colomb Med (Cali). 2016 Dec 30;47(4):203-212.

The Human Alzheimer Disease Project: Answering the Call

DeKosky ST, Growdon JH.

JAMA Neurol. 2016 Apr;73(4):373-4. doi: 10.1001/jamaneurol.2015.4512.

Influenza infections and risk of Alzheimer's disease

Imfeld P, Toovey S, Jick SS, Meier CR.

Brain Behav Immun. 2016 Oct;57:187-192. doi: 10.1016/j.bbi.2016.03.014. Epub 2016 Mar 19.

Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries

Thorpe CT, Fowler NR, Harrigan K, Zhao X, Kang Y, Hanlon JT, Gellad WF, Schleiden LJ, Thorpe JM.

J Am Geriatr Soc. 2016 Sep;64(9):1806-14. doi: 10.1111/jgs.14403. Epub 2016 Aug 22.

Alzheimer's disease, apolipoprotein E and hormone replacement therapy

Depypere H, Vierin A, Weyers S, Sieben A.

Maturitas. 2016 Dec;94:98-105. doi: 10.1016/j.maturitas.2016.09.009. Epub 2016 Sep 29.

Characteristics of Tau and Its Ligands in PET Imaging

Harada R, Okamura N, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y.

Biomolecules. 2016 Jan 6;6(1):7. doi: 10.3390/biom6010007.

Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease

Ibarria M, Alegret M, Valero S, Morera A, Guitart M, Cañabate P, Moreno M, Lara S, Diego S, Hernández J, Tantinyá N, Vera M, Hernández I, Becker JT, Ruíz A, Boada M, Tárraga L.

J Alzheimers Dis. 2016;50(2):559-66. doi: 10.3233/JAD-150455.

Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study

Ohnuma T, Toda A, Kimoto A, Takebayashi Y, Higashiyama R, Tagata Y, Ito M, Ota T, Shibata N, Arai H.

Clin Interv Aging. 2016 Jan 8;11:29-36. doi: 10.2147/CIA.S95362. eCollection 2016.

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease

Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J.

Alzheimers Res Ther. 2016 Jan 29;8:4. doi: 10.1186/s13195-016-0173-2.

Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients

Lee YM, Park JM, Lee BD, Moon E, Jeong HJ, Chung YI, Kim JH, Kim HJ, Mun CW, Kim TH, Kim YH.

J Clin Psychiatry. 2016 Jan;77(1):e8-13. doi: 10.4088/JCP.14m09740.

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy

Wattmo C, Minthon L, Wallin ÅK.

Alzheimers Res Ther. 2016 Feb 17;8:7. doi: 10.1186/s13195-016-0174-1.

Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders

Godefroy O, Bakchine S, Verny M, Delabrousse-Mayoux JP, Roussel M, Pere JJ; REFLEX study group:.

J Alzheimers Dis. 2016;51(3):815-25. doi: 10.3233/JAD-150971.

Pseudobulbar Affect or Depression in Dementia?

Chang YD, Davis MP, Smith J, Gutgsell T.

J Pain Symptom Manage. 2016 May;51(5):954-8. doi: 10.1016/j.jpainsymman.2015.12.321. Epub 2016 Feb 17.

Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease

Pasquier F, Sadowsky C, Holstein A, Leterme Gle P, Peng Y, Jackson N, Fox NC, Ketter N, Liu E, Ryan JM; ACC-001 (QS-21) Study Team.

J Alzheimers Dis. 2016;51(4):1131-43. doi: 10.3233/JAD-150376.

Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study

Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.

J Alzheimers Dis. 2016;51(4):1237-47. doi: 10.3233/JAD-150978.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias